BerandaPHS • FRA
add
Photocure ASA
Tutup sebelumnya
€5,93
Rentang tahun
€3,97 - €6,65
Volume Rata-Rata
101,00
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (NOK) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 136,67Â jt | -3,54% |
Biaya operasional | 131,26Â jt | -1,32% |
Penghasilan bersih | -7,95Â jt | -84,25% |
Margin laba bersih | -5,82 | -90,82% |
Penghasilan per saham | -0,30 | -42,86% |
EBITDA | 1,92Â jt | -66,61% |
Tarif pajak efektif | 15,56% | — |
Neraca
Total aset
Total liabilitas
| (NOK) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 238,89Â jt | -17,29% |
Total aset | 707,06Â jt | -4,33% |
Total liabilitas | 222,83Â jt | -6,13% |
Total ekuitas | 484,23 jt | — |
Saham yang beredar | 26,61 jt | — |
Harga terhadap nilai buku | 0,33 | — |
Tingkat pengembalian aset | -1,96% | — |
Tingkat pengembalian modal | -2,78% | — |
Arus Kas
Perubahan kas bersih
| (NOK) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -7,95Â jt | -84,25% |
Kas dari operasi | -473,00Â rb | -103,07% |
Kas dari investasi | -1,29Â jt | 21,11% |
Kas dari pembiayaan | -7,11Â jt | 35,21% |
Perubahan kas bersih | -8,88Â jt | -416,92% |
Arus kas bebas | -2,15Â jt | 54,62% |
Tentang
Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy. Wikipedia
Didirikan
1993
Situs
Karyawan
102
